A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
Recruiting · NCT06277219 · Registry updated 2025-07-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2025-07-08 | NCT06277219 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Latticon Antibody Therapeutics, Inc | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital of Shandong First Medical University | Jinan | China | 20 |
| D&H Cancer Research Center | Margate | United States | 5 |
| Huntsman Cancer Institute | Salt Lake City | United States | 107 |
| The First Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou | China | 1 |